A Phase 1 Study of Cabozantinib in Children and Adolescents with Recurrent or Refractory Solid Tumors, Including CNS Tumors: Trial ADVL1211, A Report from the Children’s Oncology Group

BACKGROUND: We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors. METHODS: Patients received cabozantinib tablets on a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Chuk, Meredith K., Widemann, Brigitte C., Minard, Charles G., Liu, Xiaowei, Kim, AeRang, Bernhardt, M. Brooke, Kudgus, Rachel A., Reid, Joel M., Voss, Stephan D., Blaney, Susan, Fox, Elizabeth, Weigel, Brenda J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6082380/
https://ncbi.nlm.nih.gov/pubmed/29693796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27077
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados